IP Library Granted Patent US 11,633,300
Granted Patent B2
US 11,633,300 · App. 16/806,271 · Granted Apr 25, 2023

Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device

Inventor: Eliot Lazar (Austin, TX)
Assignee: Mati Therapeutics Inc.
A61F9/0017A61F9/00772
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,633,300
App. No.
16/806,271
Granted
Apr 25, 2023
Kind
B2
Abstract

A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device.

Claims (28)

1. A device for delivering a treatment medium to an eye, comprising:

a first portion, a second portion and a treatment medium member;

wherein the first portion comprises a plug type member configured and arranged to be removably secured within a punctum of the eye and wherein the first portion secures the treatment medium member to the device;

wherein the second portion is configured and arranged to elute the treatment medium from the treatment medium member to an exterior surface of the eye, thereby controllably delivering a desired amount of the treatment medium to the eye; and,

wherein the delivery device is configured and arranged such that when at least a part of the first portion is removably inserted into the punctum, the device occludes or plugs the punctum.

2. The device of claim 1 , wherein the treatment medium member comprises a biocompatible matrix and the treatment medium.

3. The device of claim 2 , wherein the treatment medium is selected from the group consisting of thrombin inhibitors; anti-thrombogenic agents;

thrombolytic agents; fibrinolytic agents; vasospasm inhibitors; calcium channel blockers;

vasodilators; antihypertensive agents; antimicrobial agents; inhibitors of surface glycoprotein receptors; antiplatelet agents; anti-mitotics; microtubule inhibitors; anti-secretory agents; active inhibitors; remodeling inhibitors; antisense nucleotides; anti-metabolites; anti-proliferatives; anticancer chemotherapeutic agents; anti-inflammatories;

non-steroidal anti-inflammatories; anti-allergenics; antiproliferative agents;

decongestants; miotics, anticholinesterase; anti-neoplastics; immunological drugs;

hormonal agents; immunosuppressive agents; growth hormone antagonists; growth factors; inhibitors of angiogenesis; dopamine agonists; radiotherapeutic agents; peptides;

proteins; enzymes; extracellular matrix components; ACE inhibitors; free radical scavengers; chelators; antioxidants; anti-polymerases; photodynamic therapy agents;

gene therapy agents; prostaglandins; anti-prostaglandins; prostaglandin precursors and combinations thereof.

4. The device of claim 1 , wherein the treatment medium comprises a prostaglandin, anti-inflammatories, non-steroidal anti-inflammatories or immunosuppressive agents.

5. The device of claim 1 , wherein the treatment medium comprises dexamethasone or a corticosteroid.

6. The device of claim 1 , wherein the treatment medium is delivered in a controllable manner over a predetermined time period directly to the eye.

7. The device of claim 1 , wherein the treatment medium is retained in proximity to the external surface of the eye and is prevented from leaving the treatment site via a blocked punctum.

8. The device of claim 1 , wherein the first portion comprises a first end that is configured to facilitate insertion of the first portion into the punctum.

9. The device of claim 1 , wherein the first portion comprises a second end that is configured to form a support for the second body portion.

10. The device of claim 1 , wherein the first portion extends along a longitudinal axis.

11. The device of claim 1 , wherein the second portion is shaped to at least partially rest upon the punctum when the first portion is retained by the lacrimal canaliculus.

12. The device of claim 1 , wherein the second portion is bonded to the first portion via a forming, curing, or polymerization process.

13. A method for delivering a treatment medium to an eye, comprising:

providing a delivery device according to claim 1 comprising a treatment medium; and

inserting the delivery device into a punctum of the eye, whereby the treatment medium is delivered to the eye.

14. The method of claim 13 , wherein the treatment medium is formulated as a sustained release formulation with a biocompatible polymer.

15. The method of claim 13 , wherein the treatment medium is a treatment for pre- and post-operative inflammation or pain, glaucoma, inflammation, infections, or dry eye.

Continuity (6)
Continuation 15817649 · Nov 20, 2017
Continuation 14876118 · Oct 6, 2015
Continuation 13081865 · Apr 7, 2011
Continuation 11571147
Provisional Application 60585287 · Jul 2, 2004
Related Publication 20210007889A1 · Jan 14, 2021
Cited By (5)
US 1,116,103 US 1,120,314 US 12,274,865 US 12,649,031 US 12,691,227